Similarly, the discovery of epidermal growth factor receptor 2 (HER2/ERBB2) overexpression on the surface of breast cancer cells led to the development of the monoclonal antibodies trastuzumab and pertuzumab, now part of standard care for HER2 positive patients [12,13]. This evidence concerns the gene ERBB2 and breast carcinoma.